Is an Increase in Serum Magnesium One of the Causes of Cardiovascular Events Reduction in the EMPA-REG OUTCOME Study?
Abstract
The EMPA-REG OUTCOME study reported that a sodium glucose cotransporter-2 (SGLT2) inhibitor empagliflozin suppresses cardiovascular (CV) events in patients with type 2 diabetes [1]. It is noteworthy in this study that a reduction in hospitalization due to heart failure and death from CV was observed soon after the start of treatment. This rapid effect is difficult to explain by the slow-acting beneficial effect of empagliflozin on glucose and lipid metabolism. Various hypotheses have been proposed, and the ketone body hypothesis and hematocrit hypothesis have attracted attention [2]. Both hypotheses are expected to be tested in the future. Previous studies have reported that serum magnesium (Mg) increased by 0.07 0.18 mEq/L after the start of treatment with SGLT2 inhibitors [3, 4]. The EMPA-REG OUTCOME study also showed that serum Mg increased from 1.7 to 1.8 mEq/L [1]. We paid attention to an increase in Mg. Mg acts as a coenzyme for various metabolic enzymes, and magnesium deficiency is known to have a harmful effect on blood pressure and glucose metabolism. Ninety-nine percent of Mg is present within cells and only 1% is present outside cells. Hypomagnesemia is likely to reflect magnesium deficiency in the whole body, but even if Mg is within the normal range, Mg in the whole body could be deficient [5]. The risk of CV is known to be high in hypomagnesemia. According to the Framingham Heart Study, hypomagnesemia is a risk factor for atrial fibrillation [6]. Del Gobbo et…
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.